« Back
Home /
Ondansetron

Ondansetron

Item no.	HY-B0002B-50mg
Manufacturer	MedChem Express
CASRN	99614-02-5
Amount	50 mg
Quantity options	100 mg 10 mM/1 mL 10 mg 50 mg 5 mg
Category	Metabolism Regulation of Appetite Inhibitors & Compound Libraries Small Molecules
Type	Inhibitors
Specific against	other
Purity	99.46
Citations	[1]Brown AM, et al. Ion permeation and conduction in a human recombinant 5-HT3 receptor subunit (h5-HT3A). J Physiol. 1998 Mar 15;507 ( Pt 3):653-65.\|[2]Barann M, et al. Recombinant human 5-HT3A receptors in outside-out patches of HEK 293 cells: basic properties and barbiturate effects. Naunyn Schmiedebergs Arch Pharmacol. 2000 Sep;362(3):255-65.\|[3]Wildeboer KM, et al. Ondansetron results in improved auditory gating in DBA/2 mice through a cholinergic mechanism. Brain Res. 2009 Dec 1;1300:41-50.\|[4]Khedhaier A, et al. Circadian rhythms in toxic effects of the serotonin antagonist ondansetron in mice. Chronobiol Int. 2003 Nov;20(6):1103-16.\|[5]Umathe SN, et al. The 5-HT3 receptor antagonist, ondansetron, blocks the development and expression of ethanol-induced locomotor sensitization in mice. Behav Pharmacol. 2009 Feb;20(1):78-83.\|[6]Doggrell SA, et al. Cardiac safety concerns for ondansetron, an antiemetic commonly used for nausea linked to cancer treatment and following anaesthesia. Expert Opin Drug Saf. 2013 May;12(3):421-31.\|[7]Xin Wang, et al. Effectiveness of Olanzapine Combined with Ondansetron in Prevention of Chemotherapy-Induced Nausea and Vomiting of Non-small Cell Lung Cancer. Cell Biochem Biophys. 2015 Jun;72(2):471-3.\|[8]Azadeh Motavallian-Naeini, et al. Anti-inflammatory effect of ondansetron through 5-HT3 receptors on TNBS-induced colitis in rat. EXCLI J2012 Feb 22:11:30-44. eCollection 2012. Front Pharmacol. 2024 Aug 21:15:1443169.\|J Ethnopharmacol. 2024 Jan 5:117703.\|J Radiat Res Appl Sci. 2023 Dec, 16(4), 100682.\|Prog Neuropsychopharmacol Biol Psychiatry. 2022 Nov 30;110689.\|SSRN. 2023 Srep 5.\|Eur J Pharm Sci. 2023 May 22;106475.\|Int J Pharm. 2015 Dec 30;496(1):33-41.\|Patent. US20170319486A1.
Smiles	O=C1C(CN2C=CN=C2C)CCC(N3C)=C1C4=C3C=CC=C4
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	GR 38032,SN 307
Shipping Condition	Room temperature
Available
Manufacturer - Type	Reference compound
Manufacturer - Applications	Neuroscience-Neuromodulation
Manufacturer - Targets	5-HT Receptor
Shipping Temperature	Room Temperature
Storage Conditions	4°C (Powder, protect from light)
Molecular Weight	293.36
Product Description	Ondansetron (GR 38032; SN 307) is a highly selective 5-HT3 receptor antagonist, with IC50 value of 103 pM. Ondansetron exerts antiemetic effects by antagonizing 5-HT receptor located on local neurons in the peripheral and central nervous system. Ondansetron suppresses nausea and vomiting caused by chemotherapy and radiation therapy. Ondansetron has orally bioactivity[1][2][3][4][5][6][7][8].
Manufacturer - Research Area	Neurological Disease; Cancer
Solubility	DMSO: 10 mg/mL (ultrasonic)
Manufacturer - Pathway	GPCR/G Protein; Neuronal Signaling
Isoform	lactoferrin
Clinical information	Launched

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

HY-B0002B-50mg-safety-datasheet.pdf